BRPI0804623A2 - uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos - Google Patents
uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivosInfo
- Publication number
- BRPI0804623A2 BRPI0804623A2 BRPI0804623-9A BRPI0804623A BRPI0804623A2 BR PI0804623 A2 BRPI0804623 A2 BR PI0804623A2 BR PI0804623 A BRPI0804623 A BR PI0804623A BR PI0804623 A2 BRPI0804623 A2 BR PI0804623A2
- Authority
- BR
- Brazil
- Prior art keywords
- drug
- preparation
- treatment
- patients suffering
- human albumin
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 5
- 102000008100 Human Serum Albumin Human genes 0.000 title abstract 4
- 108091006905 Human Serum Albumin Proteins 0.000 title abstract 4
- 208000010877 cognitive disease Diseases 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 title abstract 4
- 208000028698 Cognitive impairment Diseases 0.000 title abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
USO DE ALBUMINA HUMANA TERAPêUTICA PARA A PREPARAçãO DE UM FáRMACO PARA O TRATAMENTO DE PACIENTES SOFRENDO DE DISTúRBIOS COGNITIVOS. A presente invenção refere-se ao uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos. A invenção é baseada no uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos, em que o modelo de administração do fármaco inclui a administração ao paciente por um mínimo de três vezes sucessivas, de uma quantidade terapeuticamente eficiente de albumina terapêutica humana por meio de troca de plasma e/ou de perfusão intravenosa, independente do conteúdo de A<225> no sangue do paciente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200702831 | 2007-10-26 | ||
| ES200702831A ES2332846B1 (es) | 2007-10-26 | 2007-10-26 | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0804623A2 true BRPI0804623A2 (pt) | 2009-06-30 |
| BRPI0804623B1 BRPI0804623B1 (pt) | 2020-02-11 |
| BRPI0804623B8 BRPI0804623B8 (pt) | 2021-05-25 |
Family
ID=40583637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0804623A BRPI0804623B8 (pt) | 2007-10-26 | 2008-10-23 | uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7851446B2 (pt) |
| EP (1) | EP2111868B1 (pt) |
| JP (1) | JP5437619B2 (pt) |
| CN (1) | CN101417123B (pt) |
| AR (1) | AR068901A1 (pt) |
| AU (1) | AU2008233025B8 (pt) |
| BR (1) | BRPI0804623B8 (pt) |
| CA (1) | CA2641830C (pt) |
| CL (1) | CL2008003133A1 (pt) |
| ES (2) | ES2332846B1 (pt) |
| MX (1) | MX2008013635A (pt) |
| NZ (1) | NZ572131A (pt) |
| PL (1) | PL2111868T3 (pt) |
| PT (1) | PT2111868E (pt) |
| RU (1) | RU2414925C2 (pt) |
| UY (1) | UY31418A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5843345B2 (ja) | 2010-07-08 | 2016-01-13 | 旭化成メディカル株式会社 | β−アミロイド除去システム |
| HUE056294T2 (hu) * | 2016-08-18 | 2022-02-28 | Alkahest Inc | Vérplazma frakciók korral összefüggõ kognitív rendellenesség kezelésére |
| US10525107B2 (en) | 2016-08-18 | 2020-01-07 | Alkahest, Inc. | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| UA127828C2 (uk) * | 2017-04-26 | 2024-01-17 | Алкахест, Інк. | Спосіб застосування фракції білків плазми крові для лікування когнітивних порушень |
| WO2020018343A1 (en) * | 2018-07-20 | 2020-01-23 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| EP3643319A1 (en) * | 2018-10-25 | 2020-04-29 | Grifols Worldwide Operations Limited | Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages |
| CA3115308A1 (en) | 2018-10-26 | 2020-04-30 | Alkahest, Inc. | Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery |
| CN116406374A (zh) | 2020-10-30 | 2023-07-07 | 深圳普罗吉医药科技有限公司 | 人血清白蛋白在治疗疾病中的应用 |
| CN117202949A (zh) * | 2021-04-30 | 2023-12-08 | 基立福环球运营有限公司 | 治疗性血浆置换和低容量血浆置换用于治疗认知损害的用途 |
| WO2025230830A1 (en) | 2024-04-29 | 2025-11-06 | Alkahest, Inc. | Compositions of blood plasma fractions and their use in treatment of spinal muscular atrophy (sma) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3612137A1 (de) | 1986-04-10 | 1987-10-15 | Biotest Pharma Gmbh | Steriles plasmaaustauschmittel |
| US5112298A (en) | 1990-06-25 | 1992-05-12 | Baxter International Inc. | Apheresis method and device |
| US5178603A (en) | 1990-07-24 | 1993-01-12 | Baxter International, Inc. | Blood extraction and reinfusion flow control system and method |
| US6627151B1 (en) * | 1997-06-13 | 2003-09-30 | Helmut Borberg | Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion |
| EP1290451B1 (en) | 2000-05-23 | 2005-12-07 | University Of Southern California | Diagnosis of alzheimer's disease using ldl receptor protein-1 |
| WO2002078670A1 (en) * | 2001-03-02 | 2002-10-10 | Neuron Therapeutics, Inc. | Neuroprotectants formulations and methods |
| AU2002366355A1 (en) | 2001-12-17 | 2003-06-30 | New York State Office Of Mental Health | SEQUESTRATION OF ABeta IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES |
| CA2500952C (en) | 2002-10-04 | 2011-04-26 | Prana Biotechnology Limited | Neurologically-active compounds |
| AU2003303198A1 (en) * | 2002-12-19 | 2004-07-14 | New York University | Method for treating amyloid disease |
| PL376644A1 (pl) | 2003-02-13 | 2006-01-09 | Octapharma Ag | Roztwór albuminy i sposób wytwarzania tego roztworu |
| EP1651195A4 (en) | 2003-07-11 | 2007-10-03 | Myriad Genetics Inc | PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE |
| AT413336B (de) * | 2003-09-12 | 2006-02-15 | Mattner Frank Dr | Apherese-vorrichtung |
| US20050182044A1 (en) | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
| AT500483B1 (de) | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
| RU2261702C1 (ru) * | 2004-09-23 | 2005-10-10 | Смирнов Алексей Владимирович | Способ лечения гипергомоцистеинемии у больных с хронической почечной недостаточностью, получающих лечение гемодиализом или гемофильтрацией |
| RU2281090C2 (ru) * | 2004-09-23 | 2006-08-10 | Алексей Владимирович Смирнов | Способ лечения больных хронической почечной недостаточностью |
| US7436304B1 (en) | 2005-07-19 | 2008-10-14 | Visible Assets, Inc | Evidence tracking |
-
2007
- 2007-10-26 ES ES200702831A patent/ES2332846B1/es not_active Expired - Fee Related
-
2008
- 2008-10-17 RU RU2008141076/15A patent/RU2414925C2/ru active
- 2008-10-17 NZ NZ572131A patent/NZ572131A/en unknown
- 2008-10-17 AR ARP080104523A patent/AR068901A1/es unknown
- 2008-10-22 PT PT83803015T patent/PT2111868E/pt unknown
- 2008-10-22 PL PL08380301T patent/PL2111868T3/pl unknown
- 2008-10-22 ES ES08380301T patent/ES2428698T3/es active Active
- 2008-10-22 EP EP08380301.5A patent/EP2111868B1/en active Active
- 2008-10-23 MX MX2008013635A patent/MX2008013635A/es active IP Right Grant
- 2008-10-23 CL CL2008003133A patent/CL2008003133A1/es unknown
- 2008-10-23 CN CN2008101705786A patent/CN101417123B/zh active Active
- 2008-10-23 BR BRPI0804623A patent/BRPI0804623B8/pt active IP Right Grant
- 2008-10-23 UY UY31418A patent/UY31418A1/es not_active Application Discontinuation
- 2008-10-24 JP JP2008274076A patent/JP5437619B2/ja active Active
- 2008-10-24 US US12/257,814 patent/US7851446B2/en active Active
- 2008-10-24 CA CA2641830A patent/CA2641830C/en active Active
- 2008-10-24 AU AU2008233025A patent/AU2008233025B8/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2332846B1 (es) | 2010-07-08 |
| US20090111740A1 (en) | 2009-04-30 |
| CN101417123B (zh) | 2012-06-27 |
| UY31418A1 (es) | 2009-05-29 |
| RU2414925C2 (ru) | 2011-03-27 |
| JP2009108059A (ja) | 2009-05-21 |
| PT2111868E (pt) | 2013-10-17 |
| PL2111868T3 (pl) | 2014-01-31 |
| AU2008233025A1 (en) | 2009-05-14 |
| AU2008233025B8 (en) | 2013-07-25 |
| MX2008013635A (es) | 2009-05-11 |
| ES2332846A1 (es) | 2010-02-12 |
| BRPI0804623B1 (pt) | 2020-02-11 |
| EP2111868B1 (en) | 2013-08-21 |
| JP5437619B2 (ja) | 2014-03-12 |
| EP2111868A1 (en) | 2009-10-28 |
| HK1126689A1 (en) | 2009-09-11 |
| BRPI0804623B8 (pt) | 2021-05-25 |
| CN101417123A (zh) | 2009-04-29 |
| NZ572131A (en) | 2010-06-25 |
| AU2008233025B2 (en) | 2013-06-27 |
| ES2428698T3 (es) | 2013-11-08 |
| AR068901A1 (es) | 2009-12-16 |
| CL2008003133A1 (es) | 2009-08-07 |
| CA2641830A1 (en) | 2009-04-26 |
| US7851446B2 (en) | 2010-12-14 |
| CA2641830C (en) | 2013-07-16 |
| RU2008141076A (ru) | 2010-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0804623A2 (pt) | uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos | |
| American Society of Anesthesiologists Task Force on Chronic Pain Management | Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine | |
| JP2022009125A5 (pt) | ||
| NZ597378A (en) | Treatment of multiple sclerosis with laquinimod | |
| EP2216024A3 (en) | Use of Ranolazine for the treatment of cardiovascular diseases | |
| BRPI0820800A2 (pt) | Dispositivo médico implantável para liberação controlada de droga, e, métodos para administração de uma droga na bexiga de um paciente e para tratar a bexiga em um paciente | |
| WO2008022189A3 (en) | Administration of high potency platinum compound formulations by inhalation | |
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| UA98136C2 (ru) | Применение аклидиния для лечения респираторных заболеваний | |
| EP3247352A1 (en) | Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function | |
| Chen et al. | Efficacy and safety of dexmedetomidine versus propofol for the sedation of tube-retention after oral maxillofacial surgery | |
| CY1115269T1 (el) | Χρηση ανταγωνιστων οπιοειδων για την παρασκευη ενος φαρμακου στη θεραπευτικη αγωγη εκφυλιστικων ασθενειων του αμφιβληστροειδους | |
| RU2013112890A (ru) | Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина | |
| BR112014004339A2 (pt) | suspensão oral | |
| RU2006101061A (ru) | Азенапин для лечения шизофрении у пациентов с избыточной массой тела или предрасположенностью к избыточной массе тела | |
| Cangemi Jr | Administration of general anesthesia for outpatient orthognathic surgical procedures | |
| WO2008079818A3 (en) | Intravenous administration of water soluble analgesic formulations | |
| Winter et al. | 0561 Solriamfetol Real World Experience Study: Safety, Efficacy, and Follow-Up for Patients with Obstructive Sleep Apnea in Germany | |
| NZ599227A (en) | Therapeutic agent for chronic pain | |
| JP2010519274A5 (pt) | ||
| Wong et al. | Sedation and Analgesia for HIFU Ablation | |
| Almomani | The effect of ketamine on blood pressure, heart rate, respiratory rate and intraocular pressure in patients undergoing ocular procedures | |
| RU2549474C1 (ru) | Способ премедикации перед оперативными гинекологическими вмешательствами, выполняемыми в условиях общей анестезии | |
| CN2912665Y (zh) | 新型输液瓶 | |
| Mitchell | Motor neurone disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: GRIFOLS, S.A. (ES) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |